262 related articles for article (PubMed ID: 12811358)
21. The special treatment.
Osborne R
Nat Biotechnol; 2008 May; 26(5):487-9. PubMed ID: 18464770
[No Abstract] [Full Text] [Related]
22. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
23. Off-label promotion.
Somberg J
Am J Ther; 2006; 13(5):387. PubMed ID: 16988530
[No Abstract] [Full Text] [Related]
24. A proposal for radical changes in the drug-approval process.
Wood AJ
N Engl J Med; 2006 Aug; 355(6):618-23. PubMed ID: 16899784
[No Abstract] [Full Text] [Related]
25. Accelerated approval seen as triumph and roadblock for cancer drugs.
Susman E
J Natl Cancer Inst; 2004 Oct; 96(20):1495-6. PubMed ID: 15494596
[No Abstract] [Full Text] [Related]
26. Food and Drug Administration: 100 years of protection.
Mosocco DJ
Home Healthc Nurse; 2007 Mar; 25(3):148-50. PubMed ID: 17353704
[No Abstract] [Full Text] [Related]
27. Disease models.
Gobburu J
Clin Adv Hematol Oncol; 2008 Apr; 6(4):241-2. PubMed ID: 18496490
[No Abstract] [Full Text] [Related]
28. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
Kane RC; Farrell AT; Sridhara R; Pazdur R
Clin Cancer Res; 2006 May; 12(10):2955-60. PubMed ID: 16707588
[TBL] [Abstract][Full Text] [Related]
29. Canadian drugs--"just say no!".
Freeman J
Iowa Med; 2003; 93(3):26. PubMed ID: 12827852
[No Abstract] [Full Text] [Related]
30. [Regulatory aspects of the drug authorization for children. USA, Europe and Germany].
Franken A
Pharm Unserer Zeit; 2009; 38(1):44-9. PubMed ID: 19132678
[No Abstract] [Full Text] [Related]
31. Dying to live.
Nat Med; 2006 Jun; 12(6):593. PubMed ID: 16760985
[No Abstract] [Full Text] [Related]
32. US court rules to allow experimental drugs for dying patients.
Waltz E
Nat Med; 2006 Jun; 12(6):596. PubMed ID: 16760988
[No Abstract] [Full Text] [Related]
33. Benefit the patient, manage the risk: a system goal.
Califf RM
Pharmacoepidemiol Drug Saf; 2004 May; 13(5):269-76. PubMed ID: 15133777
[No Abstract] [Full Text] [Related]
34. Drug testing. Regulators talk up plans for drug biomarkers ..
Couzin J
Science; 2004 Nov; 306(5699):1119. PubMed ID: 15539576
[No Abstract] [Full Text] [Related]
35. Democrats prioritize pricing, generics and drug safety.
Fox JL
Nat Biotechnol; 2007 Feb; 25(2):150-1. PubMed ID: 17287735
[No Abstract] [Full Text] [Related]
36. Pemetrexed in malignant pleural mesothelioma.
Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
[TBL] [Abstract][Full Text] [Related]
37. Marketing drugs too early in testing.
Begg CB; Brawley O; Califf RM; Demets DL; Ellenberg SS; Kaplan RS
Science; 2006 Apr; 312(5771):195. PubMed ID: 16614197
[No Abstract] [Full Text] [Related]
38. Industry looks to buck bias in emerging 'adaptive' designs.
Torres C
Nat Med; 2010 Jun; 16(6):619. PubMed ID: 20526301
[No Abstract] [Full Text] [Related]
39. How vaccines are developed.
Douglas RG
Curr Clin Top Infect Dis; 1994; 14():192-204. PubMed ID: 8086115
[No Abstract] [Full Text] [Related]
40. Moment of reckoning.
Wadman M
Nature; 2007 Apr; 446(7138):844-5. PubMed ID: 17443154
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
